On Thursday, Shares of Weatherford International plc (NYSE:WFT), gained 6.28% to $14.21.
Weatherford International, stated a net loss before charges of $33 million ($0.04 net loss per share non-GAAP) on revenues of $2.79 billion for the first quarter of 2015.
First Quarter 2015 Highlights
- International operating income margins improved 120 basis points sequentially, led by Latin America and the Middle East/North Africa/Asia Pacific region;
- Free cash flow improved $426 million over the first quarter of 2014 and capital expenditures of $224 million ($194 million net of lost-in-hole) remain in line with our reduced full-year guidance;
- As of March 31, 2015, accomplished 81% of the initial 8,000 headcount reduction plan with realized annualized savings of $422 million; and
- Reduction in force target now raised by 2,000 to 10,000 employees.
Weatherford International public limited company provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide.
Shares of Energy XXI Ltd. (NASDAQ:EXXI), gained 5.94% to $4.10, during its last trading session.
Energy XXI’s Chairman, President and Chief Executive Officer John Schiller presented at IPAA’s Oil & Gas Investment Symposium in New York on Wednesday, Apr. 22, 2015.
Energy XXI (Bermuda) Limited is engaged in the acquisition, exploration, development, production, and operation of oil and natural gas properties onshore in Louisiana and Texas, and on the Gulf of Mexico.
At the end of Thursday’s trade, Shares of Kite Pharma, Inc. (NASDAQ:KITE), gained 5.85% to $60.93.
Kite Pharma, declared that Owen Witte, M.D., director of the Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research at UCLA, is being honored at this year’s AACR conference as he receives the prestigious G.H.A. Clowes Memorial Award. In addition, Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI), has been inducted into the 2015 Class of Fellows of the AACR Academy. Dr. Witte is a scientific founder of Kite Pharma, serving on Kite’s Scientific Advisory Board, and Dr. Rosenberg is a special advisor to Kite.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
Finally, iRobot Corporation (NASDAQ:IRBT), ended its last trade with 5.84% gain, and closed at $34.09.
iRobot Corporation, declared its financial results for the first quarter ended March 28, 2015.
Financial Results
- Revenue for the first quarter of 2015 was $118.0 million, contrast with $114.2 million for the first quarter of 2014.
- Net income for the first quarter of 2015 was $4.8 million, contrast with net income of $5.3 million for the first quarter of 2014.
- Quarterly earnings per share were $0.16, contrast with earnings per share of $0.18 in the first quarter of 2014.
- Adjusted EBITDA for the first quarter of 2015 was $13.1 million, contrast with $14.2 million in the first quarter of 2014.
iRobot Corporation designs, builds, and markets robots for the consumer, defense and security, telemedicine, and mobile video partnership markets worldwide. The company operates through two segments, Home Robots, and Defense and Security Robots.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
